Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

NCT03314740 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Paclitaxel
DRUG: Cediranib
DRUG: Olaparib

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]